I don't know much about it honestly, but this article that talks about PBMs is very interesting: https://publichealth.jhu.edu/2023/eli-lilly-lowers-insulin-pri

I don't know much about it honestly, but this article that talks about PBMs is very interesting: https://publichealth.jhu.edu/2023/eli-lilly-lowers-insulin-prices https://publichealth.jhu.edu/2023/eli-lilly-lowers-insulin-p... > “Even though they're dropping their list price by 70% and capping their cost to patients at $35, it’s important for us to make this very, very clear—the company is still making a profit,” ... > During a 2019 congressional hearing, insulin makers admitted that there’s pressure to keep list prices high so that PBMs can also profit. > PBMs favor the drugs that will yield them higher profits. By lowering prices, Lilly runs the risk of being excluded from formularies, meaning the insurance companies will no longer cover the product for their patients.